Wei Shi, M.D., Ph.D.


Contact: For contact information, search the NIH Enterprise Directory.


Ph.D., Uppsala University, Sweden

M.D., TongJi Medical College of HUST, Wuhan, China

Languages Spoken: Mandarin


Dr. Shi research focuses on the design and development of pan-coronavirus vaccines and broadly neutralizing monoclonal antibodies against coronaviruses, a virus-like particle (VPL) vaccine for enterovirus-D68 (EV-D68), and protein probes for HIV, influenza, EV-D68, coronavirus, and for monoclonal antibodies discovery, such as SARS-CoV-2-S1, SARS-CoV-2 RBD and SARS-CoV-2 NTD, and hu-ACE2. He is designing a chikungunya virus (CHIKV)-based immunogen and making idiotype monoclonal antibodies to evaluate candidate vaccines against diseases such as HIV, Ebola, and malaria in animal studies and clinic trials.